Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
5 pending office actions • 4 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Rambam Med-Tech Ltd. has 5 pending office actions in Biotechnology & Pharmaceuticals. The portfolio involves 5 distinct examiners across 4 distinct art units, showing multiple examination channels with some technical-unit overlap.
TRAN, KHOA NHAT is the busiest examiner, with 1 pending action. Counsel should maintain matter-level tracking while looking for recurring issues across the art-unit assignments.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (20%) |
| Multi-statute (no §101) | 4 (80%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TRAN, KHOA NHAT | 1 | 41.9% | +50.5% |
| SALMON, KATHERINE D | 1 | 42.9% | +37.7% |
| MYERS, CARLA J | 1 | 49.5% | +46.0% |
| AUDET, MAURY A | 1 | 50.1% | +23.9% |
| FERNANDEZ, KATHERINE L | 1 | 58.0% | +37.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16835608 | INDUCING WEIGHT LOSS BY APPLICATION OF ENERGY | FERNANDEZ, KATHERINE L | 88d overdue |
| 18638775 | REWARD SYSTEM ACTIVATION FOR THERAPEUTIC PURPOSES | TRAN, KHOA NHAT | — |
| 18538027 | METHOD FOR DETERMINING SUITABILITY TO ANTI-TNF ALPHA THERAPY | SALMON, KATHERINE D | — |
| 18033582 | METHODS OF ASSESSING THE THERAPEUTIC ACTIVITY OF AGENTS FOR THE TREATMENT OF IMMUNE DISORDERS | MYERS, CARLA J | — |
| 18004821 | TYROSINE, TRYPTOPHAN AND PHENYLALANINE AS mTOR AGONISTS MEDIATING PROTEASOME DYNAMICS, COMPOSITIONS, METHODS AND USES THEREOF IN THERAPY, AND PROGNOSTIC METHODS FOR DRUG-RESISTANCE | AUDET, MAURY A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16835608 | INDUCING WEIGHT LOSS BY APPLICATION OF ENERGY | FERNANDEZ, KATHERINE L | 88d overdue |
| 18638775 | REWARD SYSTEM ACTIVATION FOR THERAPEUTIC PURPOSES | TRAN, KHOA NHAT | — |
| 18538027 | METHOD FOR DETERMINING SUITABILITY TO ANTI-TNF ALPHA THERAPY | SALMON, KATHERINE D | — |
| 18033582 | METHODS OF ASSESSING THE THERAPEUTIC ACTIVITY OF AGENTS FOR THE TREATMENT OF IMMUNE DISORDERS | MYERS, CARLA J | — |
| 18004821 | TYROSINE, TRYPTOPHAN AND PHENYLALANINE AS mTOR AGONISTS MEDIATING PROTEASOME DYNAMICS, COMPOSITIONS, METHODS AND USES THEREOF IN THERAPY, AND PROGNOSTIC METHODS FOR DRUG-RESISTANCE | AUDET, MAURY A | — |
| Art Unit | Apps |
|---|---|
| 1682 | 2 |
| 1632 | 1 |
| 1654 | 1 |
| 3798 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18638775 | REWARD SYSTEM ACTIVATION FOR THERAPEUTIC PURPOSES | TRAN, KHOA NHAT | 1632 | §103§112 | Non-Final OA | — | Pending | Apr 18, 2024 |
| 18538027 | METHOD FOR DETERMINING SUITABILITY TO ANTI-TNF ALPHA THERAPY | SALMON, KATHERINE D | 1682 | §102§103§112 | Non-Final OA | — | Pending | Dec 13, 2023 |
| 18033582 | METHODS OF ASSESSING THE THERAPEUTIC ACTIVITY OF AGENTS FOR THE TREATMENT OF IMMUNE DISORDERS | MYERS, CARLA J | 1682 | §101§112 | Non-Final OA | — | Pending | Apr 25, 2023 |
| 18004821 | TYROSINE, TRYPTOPHAN AND PHENYLALANINE AS mTOR AGONISTS MEDIATING PROTEASOME DYNAMICS, COMPOSITIONS, METHODS AND USES THEREOF IN THERAPY, AND PROGNOSTIC METHODS FOR DRUG-RESISTANCE | AUDET, MAURY A | 1654 | §102§103§112 | Final Rejection | — | Pending | Jan 09, 2023 |
| 16835608 | INDUCING WEIGHT LOSS BY APPLICATION OF ENERGY | FERNANDEZ, KATHERINE L | 3798 | §103§112 | Final Rejection | 88d overdue | Pending | Mar 31, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialRambam Med-Tech Ltd. has 5 pending office actions as of October 2026, spread across 4 art units and 5 examiners.
Khoa Nhat Tran has the most, with 1 of Rambam Med-Tech Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
